Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 10, Issue 1, Pages e003853
Publisher
BMJ
Online
2022-01-25
DOI
10.1136/jitc-2021-003853
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
- (2021) Daniel J. Olson et al. JOURNAL OF CLINICAL ONCOLOGY
- Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist
- (2020) Giulia Parisi et al. Nature Communications
- Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.
- (2020) Ines Pires Da Silva et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
- (2019) Alexander C. Huang et al. NATURE MEDICINE
- Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 (Her2) Driver Mutations
- (2019) Joshua R. Veatch et al. Cancer Immunology Research
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Comprehensive Immune Monitoring of Clinical Trials to Advance Human Immunotherapy
- (2019) Felix J. Hartmann et al. Cell Reports
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
- (2019) Spencer C. Wei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
- (2019) David Liu et al. NATURE MEDICINE
- Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells associate with clinical outcomes in NHL
- (2018) John Rossi et al. BLOOD
- Non-conventional Inhibitory CD4 + Foxp3 − PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity
- (2018) Roberta Zappasodi et al. CANCER CELL
- Mechanisms of Resistance to PD-1 and PD-L1 Blockade
- (2018) Theodore S. Nowicki et al. CANCER JOURNAL
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
- (2018) Scott J. Rodig et al. Science Translational Medicine
- Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
- (2018) Priyanka B. Subrahmanyam et al. Journal for ImmunoTherapy of Cancer
- Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data
- (2017) Julien Racle et al. eLife
- Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response
- (2017) Qiong Xue et al. Journal for ImmunoTherapy of Cancer
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Highly multiplexed profiling of single-cell effector functions reveals deep functional heterogeneity in response to pathogenic ligands
- (2015) Yao Lu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Achieving high-sensitivity for clinical applications using augmented exome sequencing
- (2015) Anil Patwardhan et al. Genome Medicine
- Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies
- (2015) D. B. Johnson et al. Cancer Immunology Research
- Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy
- (2013) Chao Ma et al. Cancer Discovery
- STAR: ultrafast universal RNA-seq aligner
- (2012) Alexander Dobin et al. BIOINFORMATICS
- A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells
- (2011) Chao Ma et al. NATURE MEDICINE
- Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma
- (2011) Bianca Devitt et al. Pigment Cell & Melanoma Research
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started